CSL Ltd
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
130 / 1361
Position in country
1163 / 5413
Return on Assets, %
6.9
-40.3
Net income margin, %
23.8
-180
EBITDA margin, %
37.8
-168.2
Debt to Equity, %
70.4
3.2
Intangible assets and goodwill, %
44.1
0.2
Revenue CAGR 3Y, %
13.3
12.5
Revenue Y, % chg
21.1
0
P/E
36
31
P/BV
5.1
1.8
P/S
6.2
10.3
EV/S
7.1
7.5
EV/EBITDA
22.5
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
125.6
131.1
Forward P/E
26.9
21.4
Dividend Yield, %
1.3
1.1
Forward Dividend Yield, %
3.3
0.1
Expected dividend per share
3
0
Payout Ratio, %
48.4
0
Dividend Ex Date
2024-03-11
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
CSL Ltd
00%
-
Telix Pharmaceuticals Ltd
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Genmab A/S
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
AbbVie Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Australia
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
88975.9
Ticker
CSLLY.PK
ISIN
US12637N2045
IPO date
1994-06-08
Availability on Russian exchanges
No
Reporting for
2024-02-13
Date fact. publication of reports
2023-12-31
Company Description
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: